

**Amendments to the Claims:**

Per 37 C.F.R. §1.121, the current status of all the claims in the present application is presented below, amended claims are notated to indicate changes made and the text of pending claims not being amended are presented without notation.

Amendments to the following are indicated by underlining what has been added and striking-through what has been deleted.

**Listing of Claims:**

1. (currently amended) A fusion protein comprising a first polypeptide comprising of at least 90% identity to a sequence of amino acid residues that is at least 90% identical to residues 41 to 148 of as shown in SEQ ID NO:2 and comprising a second cytokine polypeptide or fragment thereof, wherein the fusion protein binds a receptor as shown in SEQ ID NO:115.

2. (Previously presented) The fusion protein of claim 1, wherein the second polypeptide is selected from the group consisting of IL-2 as shown in SEQ ID NO:111.

3-9. (canceled).

10. (Previously presented) The fusion protein of claim 1, wherein the first polypeptide of at least 95% identity to a sequence of amino acid residues as shown in SEQ ID NO:2.

11. (Previously presented) The fusion protein of claim 1, wherein the first polypeptide is the sequence of amino acid residues as shown in SEQ ID NO:2 and wherein the second polypeptide is IL-2 as shown in SEQ ID NO:111.

12. (Previously presented) The fusion protein of claim 1, wherein the first polypeptide is a sequence of amino acid residues as shown in SEQ ID NO: 2 from residue 32 to residue 162.